Ladder Capital Corp
Change company Symbol lookup
Select an option...
LADR Ladder Capital Corp
NEMD iNeedMD Holdings Inc
CVS CVS Health Corp
CMI Cummins Inc
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc

Financials : Mortgage Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Ladder Capital Corp is a commercial real estate finance company. The Company's segments include loans, securities, real estate and corporate/other. The loans segment includes mortgage loan receivables held for investment (balance sheet loans) and mortgage loan receivables held for sale (conduit loans). The securities segment consists of all of its activities related to commercial real estate securities, which include investments in commercial mortgage-backed securities (CMBS) and United States Agency Securities. The real estate segment includes net leased properties, office buildings, a warehouse and condominium units. The Corporate/other segment includes the Company's investments in joint ventures, other asset management activities and operating expenses. The Company invests primarily in loans, securities and other interests in the United States commercial real estate, with a focus on senior secured assets.

Closing Price
Day's Change
0.10 (1.35%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

UPDATE: Gilead coronavirus drug use expanded to include moderate cases

5:10 pm ET August 28, 2020 (MarketWatch)

Wallace Witkowski

Gilead Sciences Inc. (GILD) said late Friday it received emergency U.S. approval for treatment for COVID-19 patients with a moderate form of the disease.

Gilead said the Food and Drug Administration expanded it emergency use of the antiviral drug Veklury, also known as remdesivir, to treat moderate cases of COVID-19 in hospitals, instead of just severe cases.

The expansion is based on data from a late-stage clinical trial ( that showed that COVID-19 patients given Veklury along with standard treatment were 65% more likely to show an improvement than patients given standard treatment alone, Gilead said.

Shares of Gilead were up 0.8% after hours, following a 0.4% decline in the regular session to close at $65.26. Gilead shares are up 0.4% for the year, compared with an 8.6% gain in the S&P 500 index .

-Wallace Witkowski; 415-439-6400;

(END) Dow Jones Newswires

August 28, 2020 17:10 ET (21:10 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.